Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine

Singapore Medical Journal

Volumn 48, Issue 9, 2007, Pages 834-839

  Tan, H J ^a   Teh, H S ^a   Raymond, A A ^a   Loo, Chee Yean ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Acute migraine; Celecoxib; Drug side effects; Gastric pain; Migraine; Naproxen sodium; Visual analogue score

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; INTERNATIONAL HEADACHE SOCIETY; MALE; MEDICAL SOCIETY; MIGRAINE; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH PAIN; VISUAL ANALOG SCALE; ACUTE DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 35848948631     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997; 48(3 suppl 3):S4-9.
2. The Headache Classification Committee. Diagnostic criteria: migraine. In: International Headache Society Members' Handbook. Oxford: Scandinavian University Press, 2000:54-63.
3. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115-27.
4. Marry J, Michael B. Non steroidal anti-inflammatory drugs in the treatment of migraine. Curr Med Res Opin 2001; 17:26-32.
5. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 1995; 15 Suppl 15:14-20.
6. Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985; 5:107-13.
7. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainous. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995; 45:577-84.
8. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004; 24:417-24.
9. Talley JJ. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Med Chem 1999; 36:201-34.
10. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-7.
11. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004; 62:1552-7.
12. Piovesan EJ, Zukerman E, Kowacs PA, Werneck LC. COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases. Celphalalgia 2002; 22:197-200.
13. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-102.
14. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.
15. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-91.
16. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-9.
17. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology 2004; 63:427-35.